Cargando…
A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy
As a malignant tumor, liver cancer is mainly treated with chemotherapy, while chemotherapeutic drugs, such as doxorubicin (DOX), may lead to toxicity, drug resistance and poor prognosis. The targeted delivery systems of combining natural products and chemotherapeutic drugs are useful to eliminate ca...
Autores principales: | Chen, Lixia, Lan, Jinshuai, Li, Zhe, Zeng, Ruifeng, Wang, Yu, Zhen, Lu, Jin, Haojieyin, Ding, Yue, Zhang, Tong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416271/ https://www.ncbi.nlm.nih.gov/pubmed/36015311 http://dx.doi.org/10.3390/pharmaceutics14081685 |
Ejemplares similares
-
A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis
por: Wei, Zeliang, et al.
Publicado: (2020) -
Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery
por: Yang, Yishun, et al.
Publicado: (2018) -
In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity
por: Chen, Chih-Tai, et al.
Publicado: (2015) -
Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats
por: Ji, Lixia, et al.
Publicado: (2017) -
Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients: a retrospective, single-institutional cohort study
por: Tan, Zhichao, et al.
Publicado: (2022)